Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
Durect (DRRX) Reports Q2 Loss, Tops Revenue Estimates
DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of DURECT Corporation (NASDAQ: DRRX)
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
DRRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of DURECT Corporation Is Fair to Shareholders
Shareholder Alert: The Ademi Firm Investigates Whether DURECT Corporation Is Obtaining a Fair Price for Its Public Shareholders
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
DURECT Corporation (DRRX) Q4 2024 Earnings Call Transcript
Durect (DRRX) Reports Q4 Loss, Lags Revenue Estimates
DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update
DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence
Durect (DRRX) Upgraded to Strong Buy: Here's Why
New Strong Buy Stocks for January 9th
Durect (DRRX) Upgraded to Buy: Here's What You Should Know
DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million
DURECT Corporation (DRRX) Q3 2024 Earnings Call Transcript
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates
DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
DURECT Corporation (DRRX) Q2 2024 Earnings Call Transcript
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update
Are Medical Stocks Lagging DURECT (DRRX) This Year?
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis
DURECT Corporation (DRRX) Q1 2024 Earnings Call Transcript
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)
DURECT Corporation (DRRX) Q3 2023 Earnings Call Transcript
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update